The ointment has annual sales of approximately $23.2 million.
The medicine is used to treat eczema, dermatitis, allergies, rashes etc.
Desonide reduces the swelling, itching and redness that can occur in these types of conditions.
The United States Food & Drug Administration gave approval for a dosage of 0.05%.
Glenmark said its current portfolio consists of 126 products authorized for distribution in the U.S. marketplace and 61 ANDA’s pending approval with the U.S. FDA.
“In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio,” it said.